Aethlon Medical's Hemopurifier® Trial Shows Promise in Cancer Treatment Advances

Aethlon Medical Advances in Cancer Treatment with Hemopurifier® Trial Success

Aethlon Medical, Inc. is making notable strides in cancer treatment through its ongoing trials of the Hemopurifier®, particularly in Australia. The company announces that the first treatment cohort in its cancer trial has been successfully completed, with no serious adverse events or dose-limiting toxicities reported among participants. This trial targets patients with solid tumors that have shown resistance to anti-PD-1 immunotherapy, a common treatment for various cancers. The successful tolerance of the Hemopurifier's four-hour treatment by all participants is a promising indicator of its potential effectiveness, as it suggests the procedure can be safely administered without significant side effects.

In a strategic move to enhance patient inclusion, Aethlon has amended its trial protocol. The revised guidelines now allow patients undergoing any treatment regimen, including anti-PD-1 agents like pembrolizumab (Keytruda®) and nivolumab (Opdivo®), to participate in the study. This broadens the eligibility criteria, enabling the recruitment of a more diverse patient population and increasing the potential for impactful results. Preclinical data supporting the Hemopurifier's efficacy highlights a remarkable 98.5% removal rate of platelet-derived extracellular vesicles during simulated treatments, underscoring the device’s innovative approach to addressing cancer-related complications.

Financially, Aethlon demonstrates a commitment to operational efficiency, reporting a 31.6% reduction in operating expenses, which bolsters its capacity to fund ongoing research and development. The independent Data Safety Monitoring Board (DSMB) has reviewed safety data from the initial cohort and has greenlit the advancement to a second cohort, where participants will receive two Hemopurifier treatments within a week. With all clinical sites in Australia actively screening for this next cohort under the amended protocol, Aethlon is aligning its research with contemporary care standards and expanding its potential market reach. A conference call scheduled for today at 4:30 p.m. ET will further elaborate on these developments, offering insights into the company’s strategic direction.

In addition to its cancer initiatives, Aethlon is advancing its collaboration with UCSF on Long COVID research, with recent findings presented at the Keystone Symposium. This involvement reflects Aethlon's broader commitment to addressing significant medical challenges in oncology and infectious diseases. As the company prepares for its upcoming quarterly earnings report, stakeholders are keenly focused on these developments, which are essential for understanding Aethlon's financial performance and strategic positioning in the biotech landscape.